English
Home > Products > Dexmedetomidine

China Dexmedetomidine Factory

Our goal is to satisfy our customers by offering golden service, good price and high quality for Dexmedetomidine,CAS NO 145108-58-3,145108-58-3,Dexmedetomidine API, Our products are strictly inspected before exporting , So we gain a good reputation all over the world. We looking forward to cooperation with you in the future.
Dexmedetomidine, We've got constantly insisted on the evolution of solutions, spent good funds and human resource in technological upgrading, and facilitate production improvement, meeting the wants of prospects from all countries and regions.

Related Products

Hot Products

  • 2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate

    2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate

    Product Name:2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate
    Molecular Formula:C23H19F2N3O6
    Molecular Weight:471.41
    CAS Registry Number:134790-39-9
  • 2-Chloro-5-trifluoromethylpyridine

    2-Chloro-5-trifluoromethylpyridine

    Product Name:2-Chloro-5-trifluoromethylpyridine
    Molecular Formula:C6H3ClF3N
    Molecular Weight:181.54
    CAS Registry Number:52334-81-3
  • Desogestrel

    Desogestrel

    Product Name:Desogestrel
    Molecular Formula:C22H30O
    Molecular Weight:310.47
    CAS Registry Number;54024-22-5
  • Borane ammonia complex

    Borane ammonia complex

    Product Name:Borane ammonia complex
    Molecular Formula:BH6N
    Molecular Weight:30.87
    CAS Registry Number:13774-81-7
  • ecteinascidin 743

    ecteinascidin 743

    Product Name:ecteinascidin 743
    Molecular Formula:C39H43N3O11S
    Molecular Weight;761.84
    CAS Registry Number;114899-77-3
  • Mezlocillin sodium

    Mezlocillin sodium

    Product Name:Mezlocillin sodium
    Molecular Formula:C22H27N6NaO9S2
    Molecular Weight;606.6
    CAS Registry Number;59798-30-0
  • Related Blog
  • Reviews

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

Dexmedetomidine advance intermediateDexmedetomidine APIDexmedetomidine intermediate

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept